Lanreotid Zentiva

Lanreotide, the active ingredient in Lanreotid Zentiva, is a somatostatin analog presented as a subcutaneous formulation for subcutaneous use. It is employed to treat acromegaly and neuroendocrine tumors in adult patients. GNH USA supplies Lanreotid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lanreotid Zentiva is a somatostatin analog used in endocrine disorders and neuroendocrine tumor management. Acromegaly: reduces growth hormone and IGF‑1 levels to control disease activity. Neuroendocrine tumors (e.g., carcinoid tumors): suppresses tumor‑related hormone secretion and stabilises disease. Prevention of recurrence of acromegaly after surgery: maintains hormonal control post‑operatively.

Lanreotid Zentiva may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Injection site pain or erythema - Abdominal discomfort or cramps - Diarrhoea - Nausea - Headache - Flushing

Serious or Rare Side Effects: - Gallstone formation or biliary sludge - Hyperglycaemia or new‑onset diabetes mellitus - Pancreatitis or elevated pancreatic enzymes - Severe allergic reactions (anaphylaxis, angioedema) - Cardiac arrhythmias or conduction abnormalities

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Monitor blood glucose: patients may develop hyperglycaemia. - Assess gallbladder health: risk of gallstone formation. - Check for hypersensitivity: avoid in patients with known allergy to lanreotide. - Use caution in cardiac disease: monitor ECG if arrhythmias are a concern. - Adjust in hepatic or renal impairment as clinically indicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotid Zentiva can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant use with cyclosporine: may increase lanreotide plasma levels. - Co‑administration with other somatostatin analogs: additive hormonal suppression.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: blood glucose may rise, requiring dose adjustment. - CYP450 substrates (e.g., midazolam): potential alteration of metabolism. - QT‑prolonging drugs: monitor cardiac rhythm for additive effects.